This document is an excerpt from the EUR-Lex website
Document 62015CN0124
Case C-124/15: Request for a preliminary ruling from the Finanzgericht Hamburg (Germany) lodged on 12 March 2015 — Salutas Pharma GmbH v Hauptzollamt Hannover
Case C-124/15: Request for a preliminary ruling from the Finanzgericht Hamburg (Germany) lodged on 12 March 2015 — Salutas Pharma GmbH v Hauptzollamt Hannover
Case C-124/15: Request for a preliminary ruling from the Finanzgericht Hamburg (Germany) lodged on 12 March 2015 — Salutas Pharma GmbH v Hauptzollamt Hannover
OJ C 178, 1.6.2015, p. 9–9
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
1.6.2015 |
EN |
Official Journal of the European Union |
C 178/9 |
Request for a preliminary ruling from the Finanzgericht Hamburg (Germany) lodged on 12 March 2015 — Salutas Pharma GmbH v Hauptzollamt Hannover
(Case C-124/15)
(2015/C 178/09)
Language of the case: German
Referring court
Finanzgericht Hamburg
Parties to the main proceedings
Applicant: Salutas Pharma GmbH
Defendant: Hauptzollamt Hannover
Question referred
Is the Combined Nomenclature in Annex I to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and the statistical nomenclature and on the Common Customs Tariff (1), as amended by Commission Regulation (EC) No 1777/2001 of 7 September 2001 (2) to be interpreted as meaning that effervescent tablets with a calcium content of 500 mg per tablet that are used for the prevention and treatment of a calcium deficiency and to support a special therapy for the prevention and treatment of osteoporosis and for which the maximum recommended daily dose for adults indicated on the label is 3 tablets (= 1 500 mg) are to be classified under subheading 3004 9000?